PFE Stock Price Today (October 2026) — Pfizer Inc. Analysis & Key Metrics 2026-10-08
Pfizer Inc. (PFE) is trading at $27.82, down 0.64% today (as of October 2026). The stock continues to show mixed signals with a short-term dip within a broader uptrend, attracting attention from investors looking for Healthcare growth opportunities.
- According to consensus analyst estimates, the 1-year price target is $28.61 (2.8% upside).
- Volatility is low (12.83% annualized), implying relatively contained price movements for short-term traders.
- The fundamental picture, based on the latest financial filings, is nuanced: steady revenue (2.60% YoY) alongside competitive pressures in the Drug Manufacturers - General space.
PFE Stock Analysis: Key Metrics & Valuation (October 2026)
Concise, actionable data for investors
Pfizer Inc. - Historical Price & Volume
- Price
- Volume
- Latest price
Market Cap
Enterprise Value: $210.34B
P/E Ratio
Forward P/E: 9.83
Revenue Growth
Year over Year
Analyst Target
+2.8% upside potential
Key Investor Questions About PFE
What investors need to know before buying
Based on current market data, PFE presents a neutral technical setup with mixed signals fundamentals.
- Technicals say: Neutral (RSI 46.80)
- Fundamentals say: Mixed signals (nuanced financial profile)
PFE's growth trajectory depends on its ability to expand within the Drug Manufacturers - General sector while managing margin pressures.
- Future growth will depend on performance in core Drug Manufacturers - General operations.
- The ability to manage competitive pressures will be crucial for sustained growth.
The primary risks for PFE investors include debt exposure and competitive dynamics in the Drug Manufacturers - General industry.
- $63.48B in debt could be a headwind in a high-rate environment.
- Fierce competition from established players in Drug Manufacturers - General.
52-Week Trading Range
Over the past year, PFE stock traded between $23.62 and $29.21 and currently trades in the middle of that range. Big swings are less likely unless a major catalyst emerges.
Volatility & Risk Profile
With 12.83% annualized volatility and β=0.39, the stock exhibits low sensitivity to market moves—making PFE suitable for investors comfortable with active risk management.
Institutional & Insider Ownership
High institutional ownership with low short interest suggests steadier hands and low immediate risk.
Analyst Sentiment & Price Targets
Latest News & Headlines
Recent headlines and coverage
Pfizer (PFE) Targets Air Traffic Fees Over Unpaid Vaccines. Can it Turn a Court Win Into Cash?
On September 13, 2026, the Wall Street Journal reported that Pfizer Inc. (NYSE:PFE) is enforcing a Belgian court judgment against Poland and Romania over unpaid COVID-19 vaccine orders by targeting an unusual source of leverage: air traffic control fees. Eurocontrol, the intergovernmental body that coordinates European air traffic management, has frozen transfers of airline route […]
AbbVie vs. Pfizer: Which Healthcare Stock Makes Your Portfolio Healthier in 2026?
AbbVie pivots toward newer immunology drugs while Pfizer leans on acquisitions to offset pandemic decline, but their financial profiles and valuations tell starkly different stories.
Pfizer Stock Paid Out $49B: So Why Did Investors Lose Money?
The pharmaceutical giant sent shareholders a torrent of cash, yet the stock itself went backward. Here is the accounting of what owners actually received.
What Could Pfizer (PFE) Unlock From Faster FDA Reviews And Orphan Drug Growth?
Pfizer (NYSE:PFE) is focusing more of its research pipeline on therapies eligible for FDA Breakthrough Therapy and orphan drug status. The FDA has widened use of Breakthrough Therapy designations in areas such as oncology, which can shorten review and approval timelines. Global orphan drug markets are expanding in value as genomics, faster approvals, and government incentives support treatments for rare diseases. The growing role of Breakthrough Therapy labels and orphan drugs for Pfizer is...
Could a New Vaccine Formula XFG Give Pfizer (PFE) and BioNTech (BNTX) a Post-Pandemic Revenue Boost?
Pfizer Inc. (NYSE:PFE) and BioNTech SE (NASDAQ:BNTX) announced on August 27 that the U.S. FDA has approved the supplemental Biologics License Application for their 2026–2027 COVID-19 vaccine formula, COMIRNATY XFG. The updated formula targets the XFG variant and is authorized for adults aged 65 and older, as well as individuals aged 5 to 64 with […]
Was Moderna Stock's Cancer Vaccine Run Visible In Advance?
Moderna (MRNA) stock rose roughly 510% over the year to September 21, 2026, climbing from about $25 to about $173. The S&P 500 gained 18.5% with dividends reinvested over the same window, and Pfizer (PFE) about 23%. The run's central event came on August 19, 2026, when Merck and Moderna said a Phase III trial of their cancer vaccine, intismeran autogene, met its endpoints in melanoma. A rough timetable for the trial was public long before the stock moved, but its result was not.
Should Dividend Investors Buy Pfizer Stock for Its High Yield or Invest in Eli Lilly for Its Dividend Growth?
When investing in a dividend stock, it's important to consider not just the yield, but also the potential for dividend growth and overall risk.
Pfizer Refocuses Growth Strategy as New Products Offset COVID Decline
Pfizer (NYSE:PFE) has rebuilt its commercial model around newer and acquired products while reducing exposure to its COVID-19 franchise, according to Alexandre de Germay, the company’s chief international commercial officer and executive vice president. Speaking with Chris Schott at a company event
AbbVie vs. Pfizer: Which Dividend Stock Is the Better Buy in September?
These companies are committed to rewarding shareholders.
How Investors Are Reacting To Pfizer (PFE) Easing Policy Pressures And New HHS Revenue-Sharing Deal
Earlier this month, Pfizer’s CEO Albert Bourla told investors at Morgan Stanley’s Global Healthcare Conference that major headwinds such as tariffs, drug-pricing pressures, declining COVID-19 sales and upcoming patent expiries are beginning to ease, supported by cost actions and a growing mix of newer therapies. At the same time, Pfizer’s agreement to share a portion of any additional overseas pricing revenue with the U.S. Department of Health and Human Services, alongside management’s...
Explore More Analysis for PFE
Additional research, tools, and technical breakdowns
Stock Analyzer Report
Deep-dive automated research and stock rating report.
DCF Fair Value Calculator
Discounted cash flow model and intrinsic value projection.
AI Price Predictions
Multi-scenario price predictions and consensus targets.
Insider Activity Tracker
Track buying/selling behavior of corporate insiders.
Earnings Calendar
Track upcoming and historical corporate earnings reports.
Market Insights & Research
Read the latest analysis articles and expert research.
Earnings snapshot
Next report Nov 3, 2026 (before the open, usually)
Frequently Asked Questions
Common investor questions about Pfizer Inc.
Pfizer Inc. (PFE) is currently trading at $27.82. The RSI (14-day) is at 46.8, indicating neutral territory. Wall Street analysts have a consensus "buy" recommendation. The mean analyst price target of $28.61 implies 2.8% upside from current levels. Volatility is low at 12.8% annualized, meaning price movements are relatively contained. Investors should consider their risk tolerance, investment horizon, and portfolio diversification before making a decision.
Based on current valuation metrics for Pfizer Inc. (PFE): The trailing P/E ratio is 36.00, which is above the market average, indicating investors are pricing in higher growth expectations. The forward P/E is 9.83, lower than the trailing P/E, suggesting analysts expect earnings improvement. The PEG ratio is 2.71, above 2.0, suggesting the stock may be overvalued relative to its expected growth. Price-to-Book is 1.85. Price-to-Sales is 2.48. Valuation should be compared to Drug Manufacturers - General industry peers for context, as different sectors trade at different multiples.
Based on 26 analysts covering PFE, the consensus price target is $28.61. This represents a 2.8% upside from the current price of $27.82. The range spans from a low target of $25.00 to a high target of $35.75, reflecting varying levels of optimism among analysts. The consensus recommendation is "buy". Note: Analyst price targets are forward-looking estimates and not guarantees of future performance.
Yes, Pfizer Inc. (PFE) pays a dividend with a current yield of approximately 6.18%. The annualized dividend rate is $1.72 per share. The payout ratio is 226.3%, which exceeds 100%—this means the company is paying out more than it earns, which may not be sustainable long-term. The most recent ex-dividend date was Jul 24, 2026.
Key risks for Pfizer Inc. (PFE) investors include: 1. Unsustainable dividend payout ratio (226%) could lead to a dividend cut. 2. Broader market and macroeconomic risks (interest rates, inflation, geopolitical events). 3. Drug Manufacturers - General sector-specific competitive pressures. Investors should diversify and consider their risk tolerance before investing.
Here is Pfizer Inc.'s (PFE) current debt and financial health profile: Total debt stands at $63.48B. The debt-to-equity ratio is 0.74x, which is moderate and generally manageable for most companies. The current ratio is 1.27, indicating adequate short-term liquidity. The quick ratio is 0.85. The company holds $11.70B in cash and equivalents. Free cash flow is positive at $12.49B, providing a cushion for debt servicing and shareholder returns.